Ir directamente a la navegación principal Ir directamente a la búsqueda Ir directamente al contenido principal

Validation of the neuroinflammation cycle as a drug discovery target using integrative chemical biology and lead compound development with an Alzheimer's disease-related mouse model

  • Wenhui Hu
  • , Hantamalala Ralay Ranaivo
  • , Jeffrey M. Craft
  • , Linda J. Van Eldik
  • , D. Martin Watterson

Producción científica: Article › revisión exhaustiva

19 Citas (Scopus)

Resumen

The neuroinflammation cycle has been proposed as a potential therapeutic target in the development of new approaches to altering Alzheimer's disease (AD) progression. However, the efficacy and toxicological profile of compounds that focus only on classical NSAID targets have been disappointing to date. Therefore, we recently initiated an unbiased, integrative chemical biology approach that used a hierarchal set of cell-based screens, followed by efficacy analysis in a new AD-relevant animal model that more closely resembles human pathology endpoints in terms of neuroinflammation and neuronal loss. The prior investigations provided a proof of concept that targeting the neuroinflammation cycle may be a viable drug discovery approach for AD. However, recent informatics analyses of the high attrition rate in drug development have identified the need for starting drug development with lead compounds that are well below cut off values in computed molecular properties in order to facilitate late stage medicinal chemistry refinement to improve in vivo functions. We describe here how we are leveraging our novel, unbiased, integrative chemical biology approach for the rapid discovery of potential lead compounds for AD drug discovery. Specifically, we show that orally bioavailable compounds with the desired physical properties and in vivo functions can be identified in focused synthetic libraries composed of chemical diversifications of the inactive but privileged pyridazine molecular fragment.

Idioma originalEnglish
Páginas (desde-hasta)197-205
Número de páginas9
PublicaciónCurrent Alzheimer Research
Volumen2
N.º2
DOI
EstadoPublished - abr 2005

Financiación

FinanciadoresNúmero del financiador
National Institute on AgingT32AG000260
National Institute on Aging

    ODS de las Naciones Unidas

    Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

    1. Good health and well being
      Good health and well being

    ASJC Scopus subject areas

    • General Medicine

    Huella

    Profundice en los temas de investigación de 'Validation of the neuroinflammation cycle as a drug discovery target using integrative chemical biology and lead compound development with an Alzheimer's disease-related mouse model'. En conjunto forman una huella única.

    Citar esto